Merial

Since January 1st, 2017, Merial is part of Boehringer Ingelheim.

Improving the health and quality of life of patients is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention.

Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals. In 2017, Boehringer Ingelheim achieved net sales of nearly 18.1 billion euros. R&D expenditure, exceeding three billion euros, corresponded to 17.0 per cent of net sales.

As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.

Boehringer Ingelheim is the second largest animal health business in the world. The company is committed to creating animal wellbeing through its large portfolio of advanced, preventive healthcare products and services. With net sales of €3.9 billion and around 10,000 employees worldwide, it is present in more than 150 markets.

 

Role of Merial in the VAC2VAC project

Merial, highly engaged in the 3Rs, brings to the VAC2VAC project experience and expertise in vaccines at different levels: testing on products and final batches, whole production process, innovative non-animal analytical tools, analytical development, validation and transfer and regulatory know-how. Merial will also provide materials and reagents needed in the development of alternative, non-animal methods for consistency testing. This collaboration with the VAC2VAC consortium partners, including other vaccine industry partners, both human and veterinary, is an unique opportunity to implement science-based testing of our vaccines while reducing animal use.

Partner representatives

Nathalie MoulianNathalie Moulian will facilitate and coordinate the interfaces (scientific, technical, reagents and materials) between the consortium partners and the Merial experts.

 

 

 

 

 

Jacques LechenetJacques Léchenet (Work Package 6)

 

 

 

 

 

 

Cécile Sigoillot-Claude (Work Package 1 & Work Package 2),

Hanane El Garch and Blandine de Saint-Vis (Work Package 3 & Work Package 4)